No Data
No Data
Express News | Argenx SE : Truist Securities Raises Target Price to $540 From $480
Analysts Offer Insights on Healthcare Companies: Novartis AG (Six Swiss: CH:NOVN), Moderna (MRNA) and Argenx Se (ARGX)
A Quick Look at Today's Ratings for Argenx SE(ARGX.US), With a Forecast Between $500 to $607
On Jul 18, major Wall Street analysts update their ratings for $argenx SE(ARGX.US)$, with price targets ranging from $500 to $607.BofA Securities analyst Tazeen Ahmad maintains with a buy rating,
Argenx to Report Half Year 2024 Financial Results and Second Quarter Business Update on July 25, 2024
July 18, 2024Amsterdam, the Netherlands – argenx ((Euronext &, NASDAQ:ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that it
Stifel Nicolaus Keeps Their Buy Rating on Argenx Se (ARGX)
Argenx Se's Promising Pipeline and Strategic Growth Potential Reinforce Buy Rating
No Data